A detailed understanding of cellular immune responses in acute and chronic hepatitis is essential for the development of new drugs against hepatitis B and D infections. This means that standardised immunomonitoring under the necessary security conditions of risk level 3 is required, where immune cells can be sorted and genotypically [...]
